PLX

Peers: BMRN SNY FDMT PHAR RARE TAK CDXS DNLI AMGN PFE

| Held by: IWM IWO VTWO IWC DFAS DFAT BUSM DFMC VTWG EES

Index	RUT
Market Cap	204.99M
Enterprise Value	172.82M
Income	18.95M
Sales	80.62M
Book/sh	0.89
Cash/sh	0.51
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	226
IPO	Apr 09, 1996

P/E	11.21
Forward P/E	50.88
PEG	-
P/S	2.54
P/B	2.87
P/C	4.95
P/FCF	26.73
EV/EBITDA	6.95
EV/Sales	2.14
Quick Ratio	1.91
Current Ratio	2.94
Debt/Eq	0.13
LT Debt/Eq	0.11
Option/Short	Yes / Yes

EPS (ttm)	0.23
EPS next Y	0.05
EPS next Q	-0.02
EPS this Y	400.00%
EPS next Y	-79.17%
EPS next 5Y	-
EPS past 3/5Y	35.12% 17.78%
Sales past 3/5Y	3.45% -3.46%
EPS Y/Y TTM	181.54%
Sales Y/Y TTM	30.14%
EPS Q/Q	2190.00%
Sales Q/Q	27.07%
Earnings	Aug 12 BMO
EPS/Sales Surpr.	600.00% 53.64%

Insider Own	9.04%
Insider Trans	0.00%
Inst Own	19.56%
Inst Trans	-3.20%
ROA	20.07%
ROE	31.23%
ROIC	24.00%
Gross Margin	69.20%
Oper. Margin	28.89%
Profit Margin	23.50%
SMA20	-5.16%
SMA50	-2.73%
SMA200	6.14%
Trades

Shs Outstand	80.57M
Shs Float	73.29M
Short Float	4.15%
Short Ratio	3.84
Short Interest	3.04M
52W High	3.19 -20.24%
52W Low	1.65 54.19%
Volatility	4.06% 3.82%
ATR (14)	0.10
RSI (14)	41.99
Beta	-0.00
Rel Volume	0.41
Avg Volume	791.04K
Volume	197,524

Perf Week	-5.77%
Perf Month	-9.14%
Perf Quarter	7.35%
Perf Half Y	18.89%
Perf YTD	41.34%
Perf Year	12.08%
Perf 3Y	69.61%
Perf 5Y	119.33%
Perf 10Y	-49.12%
Recom	1.00
Target Price	11.00
Prev Close	2.57
Price	2.54
Change %	-1.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-08-20	Reiterated	H.C. Wainwright	Buy	$3 → $11
Apr-17-17	Reiterated	Rodman & Renshaw	Buy	$4 → $5
Apr-04-16	Initiated	Rodman & Renshaw	Buy	$3.50
Apr-23-15	Upgrade	Jefferies	Hold → Buy	$2 → $2.60
Nov-12-14	Reiterated	R. F. Lafferty	Buy	$8 → $5
Jan-24-14	Initiated	R. F. Lafferty	Buy	$8
May-02-12	Reiterated	Oppenheimer	Outperform	$9 → $11
May-02-12	Downgrade	Canaccord Genuity	Buy → Hold	$8 → $8
Apr-30-12	Downgrade	Auriga	Buy → Hold	$8 → $8
Oct-13-11	Initiated	Morgan Joseph	Hold
Mar-17-11	Downgrade	WBB Securities	Strong Buy → Buy	$10
Nov-09-10	Reiterated	Oppenheimer	Outperform	$10 → $12
Oct-14-10	Reiterated	UBS	Buy	$9 → $10.75
Dec-02-09	Reiterated	Hapoalim	Outperform	$10 → $12
Sep-22-09	Initiated	Canaccord Adams	Buy
Sep-02-09	Initiated	Hapoalim	Outperform	$10
Dec-01-08	Reiterated	Oppenheimer	Outperform	$6 → $4
Mar-11-08	Initiated	UBS	Buy	$6
Nov-20-07	Initiated	CIBC Wrld Mkts	Sector Outperform	$7

Show Previous Ratings

Sep-22-26 09:44AM	Netflix downgraded, SanDisk initiated: Wall Street's top analyst calls (The Fly)
Sep-08-26 06:45AM	Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences (PR Newswire)
Aug-13-26 10:01PM	Protalix BioTherapeutics, Inc. Q2 2026 Earnings Call Summary (Moby) -9.92% -5.93%
Aug-12-26 07:04PM	Protalix BioTherapeutics Inc (PLX) (Q2 2026) Earnings Call Highlights: Net Income Surges to $3. ... (GuruFocus.com) +7.82%
06:58AM	Protalix: Q2 Earnings Snapshot (Associated Press)
06:50AM	Loading…
06:50AM	Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results (PR Newswire)
Aug-05-26 06:50AM	Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026 (PR Newswire)
May-13-26 08:34PM	Protalix BioTherapeutics, Inc. Q1 2026 Earnings Call Summary (Moby)
07:02PM	Protalix BioTherapeutics Inc (PLX) Q1 2026 Earnings Call Highlights: Strong Financial Position ... (GuruFocus.com)
06:57AM	Protalix: Q1 Earnings Snapshot (Associated Press)
06:50AM	Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results (PR Newswire)
May-06-26 06:50AM	Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026 (PR Newswire)
Mar-18-26 03:00PM	Protalix BioTherapeutics Inc (PLX) Q4 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com) -20.79%
09:02AM	Protalix BioTherapeutics advances Fabry disease and gout programs during 2025 (Proactive)
07:06AM	Protalix: Q4 Earnings Snapshot (Associated Press Finance)
06:50AM	Loading…
06:50AM	Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results (PR Newswire)
Mar-11-26 06:50AM	Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026 (PR Newswire)
Mar-09-26 03:43PM	Nasdaq stays green as Middle East war sends oil above $103 (Proactive) +9.92%
10:40AM	Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen (Proactive)
Jan-05-26 06:50AM	Protalix BioTherapeutics Letter to Stockholders (PR Newswire)
Dec-17-25 06:50AM	Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement (PR Newswire)
Nov-13-25 02:05PM	Protalix BioTherapeutics Inc (PLX) Q3 2025 Earnings Call Highlights: Navigating Revenue ... (GuruFocus.com) -9.81%
06:55AM	Protalix: Q3 Earnings Snapshot (Associated Press Finance)
06:50AM	Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results (PR Newswire)
Nov-06-25 06:50AM	Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025 (PR Newswire) -6.72%
Sep-29-25 06:50PM	Protalix BioTherapeutics, Inc. (PLX) Gains Investor Confidence With Major Stake Increase (Insider Monkey)
Sep-11-25 10:55AM	Protalix BioTherapeutics to Present at Investor Summit Virtual (ACCESSWIRE)
Sep-02-25 06:50AM	Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference (PR Newswire) +5.81%
Aug-14-25 06:50AM	Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results (PR Newswire) -5.59%
Aug-07-25 12:53PM	Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025 (PR Newswire)
06:50AM	Loading…
Jul-21-25 06:50AM	Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer (PR Newswire)
Jul-18-25 06:57AM	Fabry Disease Treatment Analysis Report 2025 \| Market to Reach $3.86 Billion by 2030, Rising Fabry Disease Prevalence and Demand for Targeted Therapies Drive Growth (GlobeNewswire)
Jun-30-25 06:50AM	Protalix BioTherapeutics Added to Russell 3000 and 2000 Indexes (PR Newswire)
May-14-25 06:50AM	Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC (PR Newswire)
May-10-25 03:04AM	Protalix BioTherapeutics Inc (PLX) Q1 2025 Earnings Call Highlights: Revenue Surge and ... (GuruFocus.com)
May-09-25 07:02AM	Protalix: Q1 Earnings Snapshot (Associated Press Finance) -40.48%
06:50AM	Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results (PR Newswire)
May-05-25 06:50AM	Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025 (PR Newswire) -5.33%
Apr-10-25 09:54AM	Protalix BioTherapeutics Is A Strong Buy With Increasing Revenues And A Promising Pipeline (Seeking Alpha)
Mar-24-25 06:50AM	Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025 (PR Newswire)
Mar-22-25 05:42PM	Is Protalix BioTherapeutics (PLX) The High Growth Low Debt Stock to Invest in Now? (InsiderMonkey)
Mar-21-25 09:00AM	iAccess Alpha's Virtual Best Ideas Spring Investment Conference March 25-26, 2025 (ACCESSWIRE) +5.51%
Mar-18-25 03:01AM	Protalix BioTherapeutics Inc (PLX) Q4 2024 Earnings Call Highlights: Record Revenue Growth ... (GuruFocus.com)
Mar-17-25 06:50AM	Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results (PR Newswire) +9.38%
Mar-10-25 06:50AM	Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025 (PR Newswire)
Feb-04-25 06:50AM	Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference (PR Newswire)
Dec-23-24 06:50AM	Protalix BioTherapeutics Issues 2025 Letter to Stockholders (PR Newswire)
Dec-10-24 10:35AM	EMA validates Chiesi and Protalixs dose variation for Fabry disease (Pharmaceutical Technology)
Dec-09-24 06:30AM	Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa (PR Newswire)
Nov-15-24 02:10AM	Protalix BioTherapeutics Inc (PLX) Q3 2024 Earnings Call Highlights: Revenue Surge and ... (GuruFocus.com)
Nov-14-24 07:03AM	Protalix: Q3 Earnings Snapshot (Associated Press Finance) +13.71%
06:50AM	Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results (PR Newswire)
Nov-07-24 06:50AM	Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024 (PR Newswire)
Oct-25-24 07:18AM	Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024 (PR Newswire)
Sep-20-24 08:35AM	Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing (GlobeNewswire)
Sep-16-24 12:07PM	Life Sciences Virtual Investor Forum Agenda Announced for September 19th (GlobeNewswire)
08:35AM	Protalix BioTherapeutics to Present at the Life Sciences Investor Forum September 19, 2024 (GlobeNewswire)
Sep-04-24 06:50AM	Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire) -5.61%
Sep-03-24 06:50AM	Protalix BioTherapeutics Announces Repayment of Outstanding Senior Secured Convertible Promissory Notes (PR Newswire) +13.32%
Aug-30-24 08:38AM	Is Protalix BioTherapeutics, Inc. (PLX) The Best Rated Penny Stock To Buy According to Analysts? (Insider Monkey)
Aug-14-24 06:57AM	Protalix: Q2 Earnings Snapshot (Associated Press Finance) -10.58%
06:50AM	Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results (PR Newswire)
Aug-07-24 06:50AM	Protalix BioTherapeutics to Announce Second Quarter 2024 Financial and Business Results on August 14, 2024 (PR Newswire)
Jun-13-24 06:50AM	Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout (PR Newswire)
May-29-24 08:38AM	Protalix BioTherapeutics to Present at the 2024 BIO International Convention (PR Newswire)
May-13-24 03:05AM	Protalix BioTherapeutics Inc (PLX) Q1 2024 Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-11-24 10:27AM	Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-10-24 06:56AM	Protalix: Q1 Earnings Snapshot (Associated Press Finance) -12.00%
06:50AM	Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results (PR Newswire)
May-03-24 06:50AM	Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024 (PR Newswire)
Mar-15-24 01:17PM	Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-14-24 08:11AM	Protalix BioTherapeutics Inc Reports Revenue Growth and Net Income Gain in FY 2023 (GuruFocus.com) -9.87%
06:50AM	Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results (PR Newswire)
Mar-07-24 06:50AM	Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024 (PR Newswire)
Feb-23-24 06:50AM	Protalix BioTherapeutics to Participate in the 2024 BIO CEO & Investor Conference (PR Newswire)
Dec-26-23 06:50AM	Protalix BioTherapeutics Issues 2024 Letter to Stockholders (PR Newswire)
Nov-30-23 04:00AM	Levicept Appoints Eliot Forster as CEO (GlobeNewswire) +5.59%
Nov-07-23 09:04AM	Protalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-06-23 08:04AM	Protalix BioTherapeutics Inc (PLX) Reports Q3 2023 Financial Results (GuruFocus.com) -18.38%
06:58AM	Protalix: Q3 Earnings Snapshot (Associated Press Finance)
06:50AM	Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results (PR Newswire)
Oct-30-23 06:50AM	Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023 (PR Newswire)
Oct-09-23 06:50AM	Protalix BioTherapeutics Issues Statement Regarding Security Situation in Israel (PR Newswire) -6.71%
Sep-12-23 06:50AM	Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors (PR Newswire)
Sep-06-23 06:50AM	Protalix BioTherapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-08-23 09:14AM	Protalix BioTherapeutics, Inc. (AMEX:PLX) Q2 2023 Earnings Call Transcript (Insider Monkey)
06:51AM	PLX: Second Quarter Results (Zacks)
Aug-07-23 06:50AM	Protalix BioTherapeutics Reports Second Quarter 2023 Financial and Business Results (PR Newswire) +14.46%
Aug-01-23 06:50AM	Protalix BioTherapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference (PR Newswire)
Jul-31-23 06:50AM	Protalix BioTherapeutics to Announce Second Quarter 2023 Financial and Business Results on August 7, 2023 (PR Newswire)
Jun-08-23 06:50AM	Protalix BioTherapeutics to Host In-Person KOL Breakfast following the Approval of Elfabrio® in both the United States and the European Union for Adults with Fabry Disease (PR Newswire)
May-30-23 11:00AM	PLX: Back of the Envelope (Zacks Small Cap Research)
06:50AM	Protalix BioTherapeutics Issues Letter to Stockholders (PR Newswire)
May-23-23 06:50AM	Protalix BioTherapeutics set to join Russell 3000® Index (PR Newswire) +7.55%
May-18-23 06:50AM	Protalix BioTherapeutics Announces $20 Million Milestone Payment from Chiesi Global Rare Diseases (PR Newswire) -9.32%
May-11-23 07:59AM	PLX: FDA Approval of Elfabrio (Zacks Small Cap Research) -13.27%
May-10-23 04:16PM	Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics (Benzinga)
06:00AM	Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease (PR Newswire)
May-08-23 02:32AM	Weekly biotech pulse: Big catalysts on tap for Sarepta, Roche, Eyenovia, and more (Investing.com) -7.03%
May-05-23 07:26AM	PLX: One Down, One to Go (Zacks Small Cap Research)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bashan Dror	PRESIDENT AND CEO	Dec 19 '25	Buy	1.81	56,000	101,360	188,516	Dec 23 07:25 AM
Bar-Shalev Amos	Director	Nov 18 '25	Sale	1.87	168	314	0	Nov 19 04:34 PM

Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Hackensack, NJ.

PresidentMr. Dror Bashan

Senior VPMr. Gilad Mamlok

MBAMr. Yaron Naos B.Sc.

Vice President of Human ResourcesMs. Yael Fellous

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Protalix BioTherapeutics Inc

Upgrade your Finviz experience